annual CFO:
-$116.59M-$73.81M(-172.54%)Summary
- As of today (September 14, 2025), MLTX annual cash flow from operations is -$116.59 million, with the most recent change of -$73.81 million (-172.54%) on December 31, 2024.
- During the last 3 years, MLTX annual CFO has fallen by -$81.41 million (-231.45%).
- MLTX annual CFO is now -36713.17% below its all-time high of -$316.70 thousand, reached on December 1, 2020.
Performance
MLTX Cash from operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFO:
-$54.53M-$16.39M(-42.97%)Summary
- As of today (September 14, 2025), MLTX quarterly cash flow from operations is -$54.53 million, with the most recent change of -$16.39 million (-42.97%) on June 30, 2025.
- Over the past year, MLTX quarterly CFO has dropped by -$26.64 million (-95.52%).
- MLTX quarterly CFO is now -50484.42% below its all-time high of -$107.80 thousand, reached on March 1, 2021.
Performance
MLTX quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFO:
-$166.42M-$26.64M(-19.06%)Summary
- As of today (September 14, 2025), MLTX TTM cash flow from operations is -$166.42 million, with the most recent change of -$26.64 million (-19.06%) on June 30, 2025.
- Over the past year, MLTX TTM CFO has dropped by -$101.98 million (-158.28%).
- MLTX TTM CFO is now -52447.68% below its all-time high of -$316.70 thousand, reached on December 1, 2020.
Performance
MLTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
MLTX Cash from operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -172.5% | -95.5% | -158.3% |
| 3 y3 years | -231.4% | -162.7% | -274.7% |
| 5 y5 years | -10000.0% | - | - |
MLTX Cash from operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -231.4% | at low | -504.3% | at low | -295.9% | at low |
| 5 y | 5-year | <-9999.0% | at low | <-9999.0% | at low | <-9999.0% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | at low | <-9999.0% | at low |
MLTX Cash from operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$54.53M(+43.0%) | -$166.42M(+19.1%) |
| Mar 2025 | - | -$38.14M(-21.3%) | -$139.78M(+19.9%) |
| Dec 2024 | -$116.59M(+172.5%) | -$48.47M(+91.8%) | -$116.59M(+44.9%) |
| Sep 2024 | - | -$25.27M(-9.4%) | -$80.46M(+24.9%) |
| Jun 2024 | - | -$27.89M(+86.6%) | -$64.43M(+32.3%) |
| Mar 2024 | - | -$14.95M(+21.1%) | -$48.70M(+13.8%) |
| Dec 2023 | -$42.78M | -$12.34M(+33.4%) | -$42.78M(+1.8%) |
| Sep 2023 | - | -$9.25M(-23.9%) | -$42.03M(-0.2%) |
| Jun 2023 | - | -$12.16M(+34.7%) | -$42.13M(-17.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$9.02M(-22.2%) | -$50.73M(-9.2%) |
| Dec 2022 | -$55.89M(+58.9%) | -$11.60M(+24.0%) | -$55.89M(+8.0%) |
| Sep 2022 | - | -$9.35M(-55.0%) | -$51.75M(+16.5%) |
| Jun 2022 | - | -$20.76M(+46.3%) | -$44.42M(-9.8%) |
| Mar 2022 | - | -$14.19M(+90.4%) | -$49.25M(+40.0%) |
| Dec 2021 | -$35.18M(>+9900.0%) | -$7.45M(+269.2%) | -$35.18M(+25.4%) |
| Sep 2021 | - | -$2.02M(-92.1%) | -$28.04M(+7.8%) |
| Jun 2021 | - | -$25.60M(>+9900.0%) | -$26.02M(+6029.9%) |
| Mar 2021 | - | -$107.80K(-66.0%) | -$424.50K(+34.0%) |
| Dec 2020 | -$316.70K | -$316.70K | -$316.70K |
FAQ
- What is MoonLake Immunotherapeutics annual cash flow from operations?
- What is the all time high annual CFO for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics annual CFO year-on-year change?
- What is MoonLake Immunotherapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics quarterly CFO year-on-year change?
- What is MoonLake Immunotherapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for MoonLake Immunotherapeutics?
- What is MoonLake Immunotherapeutics TTM CFO year-on-year change?
What is MoonLake Immunotherapeutics annual cash flow from operations?
The current annual CFO of MLTX is -$116.59M
What is the all time high annual CFO for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high annual cash flow from operations is -$316.70K
What is MoonLake Immunotherapeutics annual CFO year-on-year change?
Over the past year, MLTX annual cash flow from operations has changed by -$73.81M (-172.54%)
What is MoonLake Immunotherapeutics quarterly cash flow from operations?
The current quarterly CFO of MLTX is -$54.53M
What is the all time high quarterly CFO for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high quarterly cash flow from operations is -$107.80K
What is MoonLake Immunotherapeutics quarterly CFO year-on-year change?
Over the past year, MLTX quarterly cash flow from operations has changed by -$26.64M (-95.52%)
What is MoonLake Immunotherapeutics TTM cash flow from operations?
The current TTM CFO of MLTX is -$166.42M
What is the all time high TTM CFO for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics all-time high TTM cash flow from operations is -$316.70K
What is MoonLake Immunotherapeutics TTM CFO year-on-year change?
Over the past year, MLTX TTM cash flow from operations has changed by -$101.98M (-158.28%)